Nurix Debuts Foundation Model to Predict Novel Binders for Undruggable Targets
Nurix Therapeutics presented new data at the 2025 AACR Annual Meeting supporting the capabilities of its DEL-AI platform—a machine learning–powered …
News
Eli Lilly Partners with Creyon Bio in up to $1B AI-Oligonucleotide Deal
Eli Lilly has signed a strategic partnership with Creyon Bio to develop AI-designed oligonucleotide therapeutics, committing $13 million upfront and up …
NIH Launches Initiative to Prioritize Human-Based Research Technologies
The National Institutes of Health (NIH) has launched a new initiative to expand the use of human-based research technologies while …
Axiom Bio Launches with $15M to Replace Animal Testing with AI for Drug Toxicity Prediction
San Francisco-based startup founded by Brandon White and Alex Beatson has announced $15 million in seed funding from Amplify Partners, …
Raidium Publishes Promptable CT Foundation Model for Tumor Segmentation
Raidium, a Paris-based medical AI company founded in 2022 by radiologist Dr. Paul Hérent and data scientist Pierre Manceron, focuses …
Tempus Introduces Loop, an AI-Driven Platform for Target Discovery and Validation
Tempus AI, Inc. (NASDAQ: TEM) announced the launch of Tempus Loop, a proprietary oncology-focused platform designed to streamline target discovery …
NHS Wales Pilots Paige AI Tool to Triage Cancer Cases
Paige and NHS Wales have launched a pilot project at Betsi Cadwaladr University Health Board (BCUHB) to evaluate the clinical …
Immunai and Parker Institute to Build Largest Single-Cell Dataset for Real-World Immunotherapy Research
Immunai and the Parker Institute for Cancer Immunotherapy (PICI) have announced a collaboration to build what they describe as the …
Potato Lands $4.5M to Automate Lab Work with AI and Robots
Seattle-based startup Potato has raised $4.5 million in seed funding to accelerate development of its AI platform for automating scientific …
Tempus, AstraZeneca, and Pathos Partner to Build Oncology Foundation Model Using Multimodal Data
Tempus has announced new multi-year agreements with AstraZeneca and Pathos AI to co-develop what is described as the largest multimodal …
GeneDx to Acquire Fabric Genomics to Enable AI-Powered, Decentralized Genome Interpretation
GeneDx has announced plans to acquire Fabric Genomics, a company specializing in AI-based genomic interpretation, in a move aimed at …
Elix and PRISM BioLab Partner to Tackle Hard-to-Drug Protein Targets with AI
Elix and PRISM BioLab have announced a partnership aimed at advancing drug discovery for protein-protein interaction (PPI) targets—an area long …